Online inquiry

IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8953MR)

This product GTTS-WQ8953MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL1RL2 gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_001351446.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8808
UniProt ID Q9HB29
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ8953MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6698MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ13018MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ15446MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ3590MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ11899MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ12359MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ9044MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ10403MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2439821
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW